Biotech Distilled

Substack ↗ Subscribe

Subscribe Substack ↗ About

Research Areas Modalities Phases Targets Track record Movers The Lead Compound

Home › Targets › E342K

E342K (1 companies · 1 programs)

Companies with an active program directed at E342K.

Beam Therapeutics Inc. BEAM

BEAM-302 — Alpha-1 Antitrypsin Deficiency Phase 1

Track record About Feedback Report a bug Substack ↗

This website is an encyclopedia of clinical-stage biotech companies, refreshed weekly. For informational and educational use only — not investment advice. Always verify against primary sources before making decisions.